天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Accounts of Chemical Research >>article
Accounts of Chemical Research

Accounts of Chemical Research

IF: 16.39
Download PDF

Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results.

Published:4 September 2022 DOI: 10.1177/11206721221124688 PMID: 36062617
Argyrios Chronopoulos,?Panagiotis Chronopoulos,?L O Hattenbach,?Agharza Ashurov,?James S Schutz,?Norbert Pfeiffer,?Christina Korb

Abstract

Purpose: We report visual and anatomical outcomes of chronic postoperative macular edema treated with a fluocinolone acetonide intravitreal implant.

Method: Retrospective study of chronic, post-surgical CME treated with a fluocinolone acetonide intravitreal implant. Best registered visual acuity (BRVA), central retinal thickness (CRT), and Goldmann tonometry intraocular pressure (IOP) were assessed over 24 months. The need for IOP lowering treatment, top-up therapy during follow-up, and complications were also assessed.

Results: We analyzed 16 consecutive eyes of 16 patients with chronic, post-surgical CME treated with fluocinolone acetonide intravitreal implant. Surgical indications included cataract surgery, vitrectomy plus membrane peeling and combined phaco-vitrectomy. Baseline mean BRVA of 0.8?±?0.65 logMAR improved to 0.60?±?0.4 logMAR (p?=?0.02) at 12 months and to 0.7?±?0.5 logMAR (p?=?0.32) at 24 months. At month 12, BRVA improved in 11 eyes, stabilized in 4 eyes, and decreased in 1 eye. At month 24, VA remained improved in 5 eyes, remained stabilized in 5 eyes, and decreased in 1 eye. Mean CRT decreased from 524?±?132?μm at baseline to 389?μm at month 3, 347?μm at month 6, 355?±?106?μm (p?=?0.0003) at month 12, and 313?±?83?μm (p?=?0.0001) at month 24. At 12 months, CRT improved in 13 eyes and remained unchanged in 2 eyes. At 24 months, CRT improved further in 8 eyes, and stabilized in 3 eyes. Increased IOP (≥21?mmHg) was observed only in 4 eyes, all successfully managed with topical medication. No further side effects were observed in any patient.

Conclusion: Visual and anatomic improvements were achieved by a single fluocinolone acetonide implant with few side effects up to 24 months in CME eyes with a long and heavy prior treatment history.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Fluocinolone Acetonide 67-73-2 C24H30F2O6 482 suppliers $55.00-$1674.75

Similar articles

IF:4.3

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

ACS Applied Electronic Materials Noemi Lois, Evie Gardner,etc Published: 14 July 2020